Unknown

Dataset Information

0

RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.


ABSTRACT: Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem. The BRCA1185delAG allele is a common inherited mutation located close to the protein translation start site that is thought to produce a shortened, nonfunctional peptide. In this study, we investigated the mechanisms that lead to PARPi and platinum resistance in the SUM1315MO2 breast cancer cell line, which harbors a hemizygous BRCA1185delAG mutation. SUM1315MO2 cells were initially sensitive to PARPi and cisplatin but readily acquired resistance. PARPi- and cisplatin-resistant clones did not harbor secondary reversion mutations; rather, PARPi and platinum resistance required increased expression of a really interesting gene (RING) domain-deficient BRCA1 protein (Rdd-BRCA1). Initiation of translation occurred downstream of the frameshift mutation, probably at the BRCA1-Met-297 codon. In contrast to full-length BRCA1, Rdd-BRCA1 did not require BRCA1-associated RING domain 1 (BARD1) interaction for stability. Functionally, Rdd-BRCA1 formed irradiation-induced foci and supported RAD51 foci formation. Ectopic overexpression of Rdd-BRCA1 promoted partial PARPi and cisplatin resistance. Furthermore, Rdd-BRCA1 protein expression was detected in recurrent carcinomas from patients who carried germline BRCA1185delAG mutations. Taken together, these results indicate that RING-deficient BRCA1 proteins are hypomorphic and capable of contributing to PARPi and platinum resistance when expressed at high levels.

SUBMITTER: Wang Y 

PROVIDER: S-EPMC4966309 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.

Wang Yifan Y   Krais John J JJ   Bernhardy Andrea J AJ   Nicolas Emmanuelle E   Cai Kathy Q KQ   Harrell Maria I MI   Kim Hyoung H HH   George Erin E   Swisher Elizabeth M EM   Simpkins Fiona F   Johnson Neil N  

The Journal of clinical investigation 20160725 8


Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem. The BRCA1185delAG allele is a common inherited mutation located close to the protein translation start site that is thought to produce a shortened, nonfunctional peptide. In this study, we investigated the mechanisms that lead to PARPi and platinum  ...[more]

Similar Datasets

| S-EPMC3801063 | biostudies-literature
| S-EPMC6609913 | biostudies-literature
| S-SCDT-EMM-2018-09982 | biostudies-other
| S-EPMC4102816 | biostudies-literature
| S-EPMC4731274 | biostudies-literature
| S-EPMC2579381 | biostudies-literature
| S-EPMC7352566 | biostudies-literature
| S-EPMC5972230 | biostudies-literature
| S-EPMC7946408 | biostudies-literature
| S-EPMC8323804 | biostudies-literature